logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Puretech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

Puretech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing

07/21/21, 11:10 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$68 million
Round Type
series d
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, announces that its Founded Entity, Vedanta Biosciences (“Vedanta”), completed a $68 million Series D financing and provided a pipeline update.

Company Info

Company
Vedanta Biosciences
Location
cambridge, maryland, united states
Additional Info
Vedanta Biosciences is leading the development of a potential new category of oral therapies for immune-mediated diseases using defined bacterial consortia manufactured from clonal cell banks. The Company’s approach bypasses the need to rely on direct sourcing of donor fecal material of inconsistent composition, thus overcoming challenges related to safety, quality, and scalability that limit donor-derived approaches. The clinical pipeline includes product candidates being evaluated for the treatment of C. difficile infection, inflammatory bowel diseases, advanced or metastatic cancers, and food allergy. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – that identified bacteria that induce a range of beneficial immune responses. The Company’s platform includes what is believed to be the largest library of bacteria derived from the human microbiome, high-throughput methods for bacterial consortium design, vast datasets from human interventional studies, and state-of-the-art capabilities for cGMP-compliant manufacturing of defined bacterial consortia. Vedanta Biosciences controls a foundational intellectual property portfolio covering compositions of matter and methods of use for classes of bacteria that play key roles in human health. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the interaction between the immune system and the microbiome.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.